Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive disease control in patients with RA, its impact in aspect of economic burden is less well understood. The purpose of this study is to assess the economic benefit of ADA treatment in Japanese patients with RA.
Methods: Data were taken from the first 24 weeks of a 48-week, multicenter, prospective, single-cohort study of self-reported work productivity and activity impairment in 512 Japanese patients with RA receiving ADA. Work-related outcomes were measured using the Work Productivity and Activity Impairment questionnaire for rheumatoid arthritis (WPAI/RA), including employment status (paid worker [PW] employed for ≥35hours/week, n=160, part time worker [PTW] employed for <35hours/week, n=80, or home worker [HW] non-employed, n=272), absenteeism (percentage of work time missed due to RA), presenteeism (percentage of impairment while working due to RA), percentage of overall work impairment (OWI) due to RA, and percentage of activity impairment (AI) due to RA. The Health Assessment Questionnaire-Disability Index (HAQ-DI), EuroQol-5Dimensions (EQ-5D), and disease activity score based on 28 joints count erythrocyte sedimentation rate (DAS28 ESR) were used to assess clinical response. Annually productivity loss was estimated using WPAI/RA scores and basic wages in Japanese workers 2012 by the Ministry of Health, Labor and Welfare.
Results: At week 24, disease activity measures were significantly improved. There were significant improvements in presenteeism of PWs and PTWs, in OWI of PWs, and in AI of all employment status. Changes in WPAI/RA domain scores correlated strongly with measures of clinical response. The saved productivity losses due to OWI and AI through week 24 were 7,400 USD for PWs, 1,300 USD for PTWs, and 4,700 USD for HWs. Improvements 2 in DAS28 ESR score, 0.5 in HAQ-DI score, and 0.2 in EQ-5D through one year were estimated to save 10,000 USD annually from productivity loss due to OWI in PWs (1 USD = 100 JPY in 2013).
Conclusion: ADA treatment reduced indirect cost due to work impairment in Japanese RA patients in different employment status.
Disclosure:
Y. Tanaka,
BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbvie, Daiichi-Sankyo,
2,
Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,
8,
Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,
5;
Y. Shinmura,
AbbVie GK,
3;
R. Nakajima,
AbbVie GK,
3;
T. Muramatsu,
AbbVie GK,
3;
S. Komatsu,
AbbVie GK,
3;
T. Kubo,
AbbVie GK,
3;
A. Kuroki,
AbbVie GK,
3;
A. Igarashi,
Abbvie GK., Abbott Japan Co., Ltd., Boehringer Ingelheim Japan, Inc., Novartis Pharma K.K., and Pfizer Japan Inc.,
5,
TOWA Pharmaceutical Co., Ltd.,
9;
T. Tango,
AbbVie GK., Ajinomoto Pharma, Hospira Japan Co., Ltd.,
5;
T. Takeuchi,
Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., and Asahi Kasei Medical K.K,
5,
AbbVie GK., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd.,
8,
AbbVie GK., Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., Sanofi–Aventis K.K.,
2,
Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.,
2.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/economic-impact-of-adalimumab-treatment-in-japanese-patients-with-rheumatoid-arthritis-analysis-of-24-weeks-data-from-the-anouveau-study/